Access Program for Asfotase Alfa

Registry ID

EUCTR2015-000809-39

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Alexion Pharma International Sàrl

Start date

2015-09-22

Completion date

2018-03-08

Last update

2026-08-16

Conditions

• Hypophosphatasia

Summary

To assess the safety and tolerability of subcutaneous (SC) injections of asfotase alfa administered 6 times weekly (at a dose of 1 mg/kg) or 3 times weekly (at a dose of 2 mg/kg) at the discretion of the Investigator.

Locations

• , , France

Related clinical trials

• Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
• The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia
• Natural History Study of Patients With Hypophosphatasia (HPP)
• A Prospective Sub-Study of the Global Hypophosphatasia Registry
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
• Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study

View on source registry